Burosumab - Latest Advances

Refractory Hypophosphatemia Secondary to Tumor-Induced Osteomalacia: Diagnostic Challenges and Successful Management With Burosumab.

Journal: Cureus

Published: August 13, 2025

Improvement in Physical Function Associated With Burosumab in a Patient With X-linked Hypophosphatemia: A Case Report.

Journal: Cureus

Published: August 10, 2025

Hyperparathyroidism Secondary to Burosumab Treatment.

Journal: Cureus

Published: August 05, 2025

Oral Health Status and Parental Awareness in Children with X-Linked Hypophosphatemic Rickets: A Case-Control Study.

Journal: Reports (MDPI)

Published: August 02, 2025

Burosumab prevents further height deficit in toddlers affected by XLH.

Journal: Endocrine connections

Published: July 15, 2025

Burosumab: What can it do in children and adult patients with X-linked hypophosphatemia?

Journal: Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research

Published: June 29, 2025

Approach to a Child with Hypophosphatemia.

Journal: Biomolecules

Published: June 26, 2025

Diagnosis and Management of Hypophosphatemic Disorders.

Journal: Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists

Published: June 11, 2025

Real-World Effectiveness of Burosumab in Adults with X-Linked Hypophosphataemia (XLH) in the UK.

Journal: Calcified tissue international

Published: June 05, 2025

Effect of burosumab conversion on calciuria and nephrocalcinosis in children with XLH: A real-world cohort study.

Journal: Bone reports

Published: May 28, 2025

Burosumab treatment of tumour-induced osteomalacia from a rib lesion.

Journal: BMJ case reports

Published: May 16, 2025

Burosumab treatment for fibroblast growth factor-23-associated hypophosphatemia in an adult patient with severe fibrous dysplasia in McCune-Albright syndrome: case report and review of the literature.

Journal: JBMR plus

Published: May 12, 2025

Filters

Refractory Hypophosphatemia Secondary to Tumor-Induced Osteomalacia: Diagnostic Challenges and Successful Management With Burosumab.

Refractory Hypophosphatemia Secondary to Tumor-Induced Osteomalacia: Diagnostic Challenges and Successful Management With Burosumab.

Improvement in Physical Function Associated With Burosumab in a Patient With X-linked Hypophosphatemia: A Case Report.

Improvement in Physical Function Associated With Burosumab in a Patient With X-linked Hypophosphatemia: A Case Report.

Hyperparathyroidism Secondary to Burosumab Treatment.

Hyperparathyroidism Secondary to Burosumab Treatment.

Oral Health Status and Parental Awareness in Children with X-Linked Hypophosphatemic Rickets: A Case-Control Study.

Oral Health Status and Parental Awareness in Children with X-Linked Hypophosphatemic Rickets: A Case-Control Study.

Burosumab prevents further height deficit in toddlers affected by XLH.

Burosumab prevents further height deficit in toddlers affected by XLH.

Burosumab: What can it do in children and adult patients with X-linked hypophosphatemia?

Burosumab: What can it do in children and adult patients with X-linked hypophosphatemia?

Approach to a Child with Hypophosphatemia.

Approach to a Child with Hypophosphatemia.

Diagnosis and Management of Hypophosphatemic Disorders.

Diagnosis and Management of Hypophosphatemic Disorders.

Real-World Effectiveness of Burosumab in Adults with X-Linked Hypophosphataemia (XLH) in the UK.

Real-World Effectiveness of Burosumab in Adults with X-Linked Hypophosphataemia (XLH) in the UK.

Effect of burosumab conversion on calciuria and nephrocalcinosis in children with XLH: A real-world cohort study.

Effect of burosumab conversion on calciuria and nephrocalcinosis in children with XLH: A real-world cohort study.

Burosumab treatment of tumour-induced osteomalacia from a rib lesion.

Burosumab treatment of tumour-induced osteomalacia from a rib lesion.

Burosumab treatment for fibroblast growth factor-23-associated hypophosphatemia in an adult patient with severe fibrous dysplasia in McCune-Albright syndrome: case report and review of the literature.

Burosumab treatment for fibroblast growth factor-23-associated hypophosphatemia in an adult patient with severe fibrous dysplasia in McCune-Albright syndrome: case report and review of the literature.